<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/41FCC1D1-FCA3-4A69-A663-E75DD2AAB030"><gtr:id>41FCC1D1-FCA3-4A69-A663-E75DD2AAB030</gtr:id><gtr:name>Reprocell Europe Limited</gtr:name><gtr:address><gtr:line1>Reprocell Europe Ltd,Thomson Pavilion,Todd Campus, Acre Road</gtr:line1><gtr:city>Glasgow</gtr:city><gtr:postCode>G20 0XA</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41FCC1D1-FCA3-4A69-A663-E75DD2AAB030" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>41FCC1D1-FCA3-4A69-A663-E75DD2AAB030</gtr:id><gtr:name>Reprocell Europe Limited</gtr:name><gtr:address><gtr:line1>Reprocell Europe Ltd,Thomson Pavilion,Todd Campus, Acre Road</gtr:line1><gtr:city>Glasgow</gtr:city><gtr:postCode>G20 0XA</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>23250.0</gtr:offerGrant><gtr:projectCost>31000.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3435C3F-87A2-43C2-93EA-1517D1439BB3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A3435C3F-87A2-43C2-93EA-1517D1439BB3</gtr:id><gtr:name>Clyde Biosciences Limited</gtr:name><gtr:address><gtr:line1>Biocity Scotland,Bo'Ness Road</gtr:line1><gtr:city>Motherwell</gtr:city><gtr:postCode>ML1 5UH</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1500.0</gtr:offerGrant><gtr:projectCost>2000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4EE1CA9E-208E-4C96-BD96-B3D440A1D626"><gtr:id>4EE1CA9E-208E-4C96-BD96-B3D440A1D626</gtr:id><gtr:firstName>Elaine</gtr:firstName><gtr:surname>Ferguson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131337"><gtr:id>28ABF76F-F9EB-4D42-B65E-4E94F0CAE42F</gtr:id><gtr:title>Predictive phenotypic assays to better predict drug-induced cardiotoxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131337</gtr:grantReference><gtr:abstractText>The pharmaceutical industry is in urgent need of tests that are better able to predict the clinical effectiveness and safety of new drug therapies. Current approaches are over-reliant on animal models that may not reflect human responses to drugs and often do not select drugs that translate into safe, effective treatment of diseases. Indeed around 90% of drugs entering clinical trials fail to reach the market, with safety liabilities explaining 20% of the failures. To address this problem, Biopta is developing a range of predictive tests using ethically-donated human tissues. A major drug safety concern is cardiac safety and toxicity; Biopta has already developed and offers to the market robust assays to detect drug-mediated changes in coronary blood flow and contractility. The feasibility study will investigate whether this can be extended to provide the first commercially available tests that can predict drug-induced cardiac arrythymias.</gtr:abstractText><gtr:fund><gtr:end>2013-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24750</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131337</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>